Clinical Trial Update: DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

View source ↗

Summary

A clinical trial update reports DNA analysis of samples from patients with kidney cancer receiving sorafenib in the MRC-RE05-SORCE study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Medical Research Council | Conditions: Kidney Cancer | Status: COMPLETED